[Problem] There is no
gene transduction method with high efficiency and high specificity for
skin,
subcutaneous tissue,
skin ulcer surfaces, and their constituent cells. More generally, achieving high
gene transduction efficiency
in vivo is challenging. Additionally, it is difficult to morphologically and functionally regenerate
skin appendages and to regenerate lost
peripheral tissues of the upper and lower limbs (upper arm,
forearm, hand, fingers,
thigh, lower leg, foot, toes).[Solution] This invention provides solutions to these challenges through a novel AAV (adeno-associated
virus)
capsid with high
gene transduction efficiency and high specificity for skin,
subcutaneous tissue, and
skin ulcer surface cells, as well as a novel AAV
capsid with high gene transduction efficiency and high specificity for epidermal tissue and its constituent keratinocytes. Additionally, the invention provides a novel tissue-specific
promoter with high
gene expression efficiency and high specificity for epidermal tissue and its constituent keratinocytes, and a pharmaceutical composition that enhances gene transduction efficiency by co-administering steroids alongside
in vivo gene transduction. The invention further includes a pharmaceutical composition that promotes the regeneration,
neogenesis, and functional enhancement of skin appendages through
in vivo gene transduction, thereby compensating for functional impairments of skin appendages. Additionally, it provides a research and development platform for developing methods to regenerate
peripheral and missing tissues of the upper and lower limbs, as well as a pharmaceutical composition for achieving tissue regeneration. Thus, the present invention provides methods for overcoming these challenges.